JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
12/12/17 - 13:15
DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test (426.89 KB)
29/11/17 - 19:30
Resignation of a Strategic Executive of the Company (233.58 KB)
09/11/17 - 14:15
GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED (1001.87 KB)
29/09/17 - 15:00
DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS (928.39 KB)
29/09/17 - 14:15
DiaSorin completes the acquisition of the ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (332.93 KB)
21/09/17 - 12:45
DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit (738.62 KB)
03/08/17 - 14:45
DiaSorin Group reports strong growth in revenues and profitability in Q2 2017 (1015.93 KB)
28/07/17 - 14:45
DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS (427.51 KB)
25/07/17 - 21:00
DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (443.45 KB)
10/07/17 - 13:30
DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP (197.68 KB)
26/06/17 - 9:45
DiaSorin presents its 2017-2019 Industrial Plan (479.98 KB)
23/06/17 - 9:30
DiaSorin and TECAN to collaborate in new platform development (755.46 KB)
22/06/17 - 19:45
DiaSorin and QIAGEN sign collaboration to expand Liaison test menu through adoption of select QIAGEN assays (430.67 KB)
23/05/17 - 11:45
DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders (735.43 KB)
16/05/17 - 13:00
DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality (429.25 KB)
08/05/17 - 19:30
DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow (984.86 KB)
27/04/17 - 18:45
DiaSorin - Annual General Meeting 2016 (421.04 KB)
21/04/17 - 18:45
DiaSorin receives authorization for the distribution of Zika IgM test in Europe (349.09 KB)
06/04/17 - 18:00
DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test (376.16 KB)
08/03/17 - 15:30
The Board of Directors approves the results for FY'16 (1.13 MB)
21/02/17 - 11:30
DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market (430.86 KB)
26/01/17 - 12:45
DIASORIN LAUNCHES THE LIAISON FGF 23 TEST, THE FIRST INNOVATIVE AND FULLY AUTOMATED MARKER FOR CHRONIC KIDNEY DISEASE (140.98 KB)
24/12/09 - 1:00
Financial instruments to employees (26.76 KB)
30/10/09 - 1:00
The BoD approves Q3'09 results (212.92 KB)
12/10/09 - 2:00
Strengthening of group's R&D team (99.72 KB)
08/10/09 - 2:00
2009 Financial calendar update (97.3 KB)
05/10/09 - 2:00
Financial instruments to employees (27.08 KB)
06/08/09 - 2:00
The BoD approves H1'09 results (214.79 KB)
08/06/09 - 2:00
2009 Financial calendar update (97.33 KB)
18/05/09 - 2:00
Financial instruments to employees (26.65 KB)
10/04/09 - 2:00
Corporate Governance Report at December 2008. (97.57 KB)
08/04/09 - 2:00
2009 Financial calendar update (103.88 KB)
19/03/09 - 1:00
The BoD approves FY 2008 results (221.59 KB)
20/02/09 - 1:00
Financial instruments to employees (26.39 KB)
13/02/09 - 1:00
The BoD approves Q4'08 results (170.79 KB)
28/01/09 - 1:00
2009 Financial calendar (93.96 KB)
08/01/09 - 1:00